Reimbursement Landscape in Europe

In Europe, while the European Medicines Agency (EMA) handles drug approvals centrally for most countries, each country makes its own decisions about medicine reimbursement. This separate national decision-making process means developers must work with different systems and requirements across countries.

Most European countries pay for medicines through public health systems, but they make decisions in different ways. Germany uses a statutory health insurance model, with a common national decision made on reimbursement for new therapies. The Netherlands operates a mandatory health insurance system that is privately organised but government-regulated. The Czech Republic maintains a statutory health insurance system with multiple health insurance funds, though the largest fund covers about 60% of the population. England's National Health Service (NHS) operates a tax-funded health system, with medicine reimbursement decisions generally made through central assessments. Even where national health systems exist or basic insurance packages are well defined, private insurance sometimes helps cover additional treatments.

The overall timing for drug evaluation by payers varies significantly, as does the evaluation method. These differences affect how long it takes to get medicines approved and what evidence countries need. Psychedelic therapies face unique challenges because they combine drugs with psychotherapeutic support. Unlike regular medication, they may require payment systems that cover both the drug and the therapist's time and possibly funding for local infrastructure.

This chapter explains how each country's funding system works, the challenges across markets, and what this means for psychedelic treatments.

General Reimbursement Pathways for Pharmaceuticals

Overview of European Reimbursement Systems

European healthcare systems all aim to provide universal health coverage but differ in how they balance public and private healthcare delivery. These differences affect how new treatments, including psychedelics, get paid for and delivered. European healthcare systems can be grouped by how much they rely on private versus public providers.

Germany, the Netherlands, and Belgium have significant private sector involvement, with over 60% of hospitals privately owned (Montagu, 2021). These countries use statutory health insurance (SHI), where everyone must contribute to healthcare funding, but private providers can deliver services within regulated frameworks. This framework creates a competitive market while maintaining universal coverage.

The UK, Denmark, and Sweden mainly use public healthcare systems, known as Beveridge models, funded through taxation and run by governments. The UK's NHS is a prime example, providing comprehensive healthcare free at the point of need. However, private insurance may supplement coverage for faster access to elective treatments or additional services, even within public-dominant systems.

France, Italy, and Spain use mixed systems. About 40-60% of their hospitals are private but get public funding. This approach tries to balance efficiency with fair access to healthcare, combining public funding with private service delivery to optimise healthcare provision.

Common Elements Across Countries

Pricing Regulations and Affordability Frameworks

A key goal across Europe is making medicines affordable while maintaining sustainable healthcare systems. The European Commission's pharmaceutical strategy aims to balance innovation with accessibility. While EU countries have different systems, all must follow the EU Transparency Directive, which requires clear pricing decisions while letting countries set their own prices (EP, 1988).

Most European countries use international reference pricing (IRP) to compare medicine prices across countries. Germany uses IRP in price negotiations after its AMNOG (Arzneimittelmarkt-Neuordnungsgesetz) benefit assessment. Meanwhile, the Czech Republic sets maximum prices based on the average of the three lowest prices in reference countries. This price referencing system helps control costs but can delay access if companies postpone launches in lower-priced markets to protect prices elsewhere.

Countries also consider existing treatment prices (internal price benchmarking) and use health economic modelling to assess value. This health economic evaluation often involves measuring quality-adjusted life years (QALYs). The UK's NICE typically allows £20,000-£30,000 per QALY, with flexibility for exceptional cases. The Netherlands uses sliding thresholds based on disease severity. While this approach focuses on health outcomes, it can be challenging for therapies like psychedelics that lack long-term data.

Cost-Containment Strategies and Budgetary Pressures

Countries use various strategies to manage the costs of new medicines. Many use managed entry agreements (MEAs), where payment depends on collecting more evidence or meeting performance targets. Germany allows risk-sharing agreements after benefit assessments, while the Netherlands uses financial risk-sharing for expensive treatments with uncertain long-term effects.

Budget impact analyses (BIAs) help estimate the cost of adopting new treatments across the healthcare system. The Czech Republic and the Netherlands require these analyses to check if treatments are affordable within national budgets. BIAs are particularly important for psychedelic therapies, which often have high upfront costs and might need a gradual introduction with real-world data collection.

Convergence and Flexibility in Policy Frameworks

While countries control their own pricing and reimbursement, the European pharmaceutical strategy promotes cooperation through shared best practices. The EU Joint Clinical Assessment (JCA) aims to standardise clinical evaluations across countries, speeding up market access and reducing duplicate work (EP, 2021). Economic evaluations and pricing negotiations remain under national control to address local needs and budgets.

The EU supports affordability through initiatives like the EURIPID project, which tracks medicine prices across countries. This initiative helps countries make informed decisions while maintaining flexibility in their approaches.

Time to Market Access

Variability in Access Timelines Across Europe

Patients' access to new medicines varies widely across Europe, showing problems in how treatments reach the market. It takes an average of 511 days for new treatments to get coverage in the EU and EEA countries (EFPIA, 2022; EFPIA, 2024a). This significant time delay ranges from 126 days in Germany to 804 in Poland.

Germany leads in quick access because it allows most medicines to be prescribed and reimbursed right after EMA approval, with payment details worked out later. Countries like Spain and Poland often take longer because they need multiple reviews at different levels. This disparity in access timing means patients in some countries can get new treatments much earlier than others, showing ongoing problems in creating a more unified European medicines market.

For psychedelic therapies, these differences create extra challenges. The unique treatment approach—including the potential for combining drugs with therapy—may take longer to get approved for payment. They might also need special agreements to track how well they work over time, which adds more steps to the process.

Factors Contributing to Delays

Several interconnected factors contribute to access delays. According to a London School of Economics study, lengthy marketing authorisation procedures, duplicative HTAs, and fragmented pricing negotiations create bottlenecks (Kamphuis et al., 2021). Even after EMA approval, most countries require additional national-level evaluations. Additionally, countries with regional HTA systems, such as Spain and Italy, frequently face delays due to decentralised decision-making processes.

Price-setting approaches, particularly international reference pricing (IRP), further exacerbate delays. Manufacturers may stagger market launches to prevent lower prices in certain countries from influencing pricing negotiations in higher-income markets. This “sequenced launch” approach deprioritises countries with a lower willingness to pay, often based on lower income, compounding inequalities in access.

Pricing and reimbursement complexities are particularly relevant to psychedelics. These therapies will likely have high upfront costs due to clinician time, infrastructure needs, and multiple therapy sessions. The need for flexible pricing and reimbursement models, such as value-based or outcomes-based pricing, could introduce additional delays on top of the existing negotiations over HTA recommendations and determining cost-effectiveness.

Potential Solutions and Policy Initiatives

The EU and some individual countries are trying to speed up access to new medicines. The European Commission's Transparency Directive requires countries to make pricing and reimbursement decisions within 180 days, but this is not necessarily followed (EC, n.d.). The recent EU pharmaceutical legislation package incentivises companies to seek broader and faster launches across EU Member States. Also, the introduction of an EU HTA process, the Joint Clinical Assessment (JCA), aims to eliminate the need for multiple national assessments.

At a country level, innovative payment models, such as MEAs and outcomes-based contracts, offer potential mechanisms to facilitate faster adoption while addressing uncertainty. These payment models can help treatments reach patients faster while controlling costs and reducing financial risks. Still, payers and drug developers have mixed views on the desire to implement these more commonly.

Comparative Analysis of Target Countries

After HTAs or national reimbursement evaluations, the path to getting treatments paid for and used varies between European countries. While HTAs evaluate how well treatments may work and their value for money, the following steps—such as agreeing on prices and adding treatments to healthcare systems—depend on each country's rules and systems.

This section examines how four countries—Germany, the United Kingdom, the Netherlands, and the Czech Republic—handle these steps after HTA. It shows the challenges that new treatments like psychedelics face when trying to enter these markets.

Germany

Germany's rigorous HTA process under the AMNOG framework defines its reimbursement landscape, followed by price negotiations and integration into statutory and private insurance systems. While the HTA establishes comparative clinical value, the implementation phase determines how therapies—particularly innovative ones like psychedelics—are reimbursed and accessed within the healthcare system. This phase hinges on negotiated pricing, physician willingness to prescribe, clarity in billing arrangements with insurers, and adherence to treatment protocols.

Final Steps After the AMNOG Procedure

Following a positive or conditional HTA outcome, the focus shifts to translating the assessment into practical pricing and prescription. Once the Federal Joint Committee (G-BA) determines the therapy’s added benefit, the manufacturer directly negotiates with the National Association of Statutory Health Insurance Funds (GKV-SV) to set a new price. This negotiated price applies universally to all statutory health insurers (GKV).

After agreeing to a price, statutory insurers reimburse the therapy based on the specified treatment conditions. Although outcome-based agreements are rare in Germany, there is growing interest in piloting such models for therapies with limited long-term data, allowing payers to link reimbursement to measurable patient outcomes.

Differences Between Statutory and Private Insurance

Germany’s dual insurance system—statutory (SHI/GKV) and private (PHI/PKV)—introduces variations in reimbursement flexibility. SHI covers roughly 90% of the population and adheres strictly to G-BA guidelines and negotiated prices. Physicians treating patients follow standardised reimbursement rates set by the Uniform Value Scale (EBM), which prioritises cost containment. For therapies without a demonstrated added benefit, SHI coverage may still apply but at reference price levels, limiting reimbursement to the cost of existing therapies.

Private insurance, by contrast, may offer broader access to new treatments and higher compensation rates for physicians under the Gebührenordnung für Ärzte (GOÄ) fee schedule. These insurers may adopt therapies even without full AMNOG endorsement, provided evidence supports efficacy and safety. As a result, private patients often face fewer access barriers but may encounter higher out-of-pocket expenses if coverage terms are less restrictive. For psychedelic therapies, private insurance may be more accommodating in covering both the drug and the accompanying psychotherapy.

Incentives for Physicians and Providers

Reimbursement mechanisms influence prescribing behaviours, particularly under SHI. Physicians must operate within regional budget caps when treating SHI patients and can only prescribe high-cost therapies when meeting specific budget and compensation conditions. This budget pressure may make prescribers hesitant to adopt psychedelic treatments, especially if they require prolonged therapy sessions or integration with psychotherapy.

Private insurance generally offers higher compensation rates for physicians, incentivising them to prioritise private patients for novel therapies. When developers roll out treatments in specialised centres, practitioners may also benefit from reputational gains, positioning themselves as leaders in emerging therapeutic fields. This dynamic creates an interplay between reimbursement systems that could shape the early adoption of psychedelics, particularly within private settings.

Specific Challenges for Psychedelic Therapies

Innovative therapies like psychedelics face significant challenges in Germany’s reimbursement model. Where psychedelics combine pharmacological effects with psychotherapy, this will require payers to evaluate the therapy as a unified intervention rather than as separate components. The unified treatment approach may necessitate adjustments to coverage frameworks to ensure reasonable reimbursement for drug administration and therapy delivery.

Infrastructure readiness is another hurdle, as clinics require the capacity to safely administer psychedelics, including appropriate monitoring environments and trained professionals. Without an established infrastructure, payers may impose stricter conditions, such as limiting access to designated treatment centres.

Long-term evidence requirements also remain a concern. While initial reimbursement may be granted based on short-term efficacy data, German payers may demand real-world evidence to confirm sustained effectiveness. Psychedelic therapies, which may lack long-term data at launch, could face post-marketing surveillance obligations or conditional reimbursement agreements requiring ongoing data collection to maintain coverage.

United Kingdom

In the United Kingdom, the National Institute for Health and Care Excellence (NICE) establishes the reimbursement framework through authoritative evaluations of treatments' clinical and cost-effectiveness in England and Wales. Meanwhile, Scotland relies on its Scottish Medicines Consortium (SMC) for health technology assessments. Following a positive recommendation from either body, the NHS and devolved administrations are responsible for determining how to integrate and fund these therapies within existing care structures.

Post-HTA Implementation in England and Wales

In England and Wales, a positive NICE recommendation carries legal weight, obligating the NHS to fund the treatment within 90 days of publication (The National Archives, 2013). This “funding mandate” applies to all NHS Trusts and Integrated Care Systems (ICSs). Implementation often involves operational adjustments, especially for therapies requiring complex delivery models.

NICE typically separates drug costs from non-drug costs, the latter defined under standard NHS service frameworks. For psychedelics, this could mean fragmentation in funding. NICE may recommend the drug for reimbursement based on incremental cost-effectiveness ratios (ICERs), while other NHS commissioners may take responsibility for decision-making and managing the funding of the associated non-drug services through separate budgets and funding pathways.

This compartmentalised approach can reduce the perceived cost of therapy to any one payer type. However, it also shifts the burden of decision-making for funding non-drug elements onto local NHS groups, potentially delaying full implementation if resources are constrained.

When NICE finds uncertainty in clinical evidence, like limited long-term data on psychedelic therapies, it can recommend conditional funding through Managed Access Agreements (MAAs) or Data Collection Arrangements. These agreements introduce a limited number of treatments while gathering additional real-world evidence.

Scotland’s Distinct Pathway

The Scottish Medicines Consortium (SMC) conducts evaluations separately from NICE in Scotland, though it often relies on similar evidence submissions. Unlike NICE, the SMC does not impose a national funding mandate. Instead, Health Boards decide whether to adopt recommendations, leading to potential regional variation in access.

The SMC prioritises therapies with clear evidence of added benefit and cost-effectiveness, applying willingness-to-pay thresholds as NICE (typically £20,000–£30,000 per QALY). However, Scotland’s smaller size and more centralised approach to health governance often facilitate faster implementation of therapies, particularly in cases of unmet need.

Northern Ireland and Wales

Northern Ireland generally follows NICE guidance through an “automatic endorsement” process. Wales also adheres closely to NICE, with the All Wales Medicines Strategy Group (AWMSG) occasionally supplementing evaluations for drugs not reviewed by NICE.

Implementation timelines in these regions mirror England's, with a 90-day funding requirement. However, local differences in service capacity may affect the pace of the rollout, particularly for therapies requiring specialised infrastructure or staffing. For psychedelics, this could result in phased adoption, starting with major population centres before expanding to smaller or rural areas.

Infrastructure and Service Integration Challenges

For complex therapies like psychedelics, reimbursement in the UK depends heavily on service readiness. The NHS must evaluate whether existing clinics can accommodate the therapy’s unique requirements, including supervised administration and integration sessions. Early adopters may face higher costs when establishing these services, while later entrants benefit from pre-existing infrastructure.

Developers must also account for NHS cost-containment measures. NICE’s focus on ICER thresholds means manufacturers may need to price therapies competitively, factoring in non-drug costs that the NHS could attribute to standard care. In cases where services are entirely new—such as therapy clinics tailored to psychedelics—developers may need to absorb NHS set up costs within their cost-effectiveness calculation.

The Netherlands

The reimbursement process in the Netherlands begins after a therapy successfully clears the HTA conducted by Zorginstituut Nederland (ZiN). Once the Minister of Health, Welfare, and Sport approves the treatment for inclusion in the national benefits package, the focus shifts to practical implementation, pricing negotiations, and insurer adoption. This process, while structured, allows for flexibility in how insurers manage and contract reimbursement agreements.

Inclusion in the Medicine Reimbursement System (GVS)

ZiN places approved therapies into the Geneesmiddelenvergoedingssysteem (GVS), the Dutch Medicine Reimbursement System. The GVS categorises treatments under Appendix 1A for full reimbursement without restrictions or Appendix 1B for specific conditions or limitations.

Complex therapies like psychedelics typically qualify for Appendix 1B placement. Appendix 1B listing requires clear protocols around eligibility criteria, patient monitoring, and evidence collection. These conditions can lead to phased rollouts, focusing initially on specialised centres or pilot programs before broader adoption. While listing in the GVS legally mandates insurers to provide coverage, national-level negotiations determine pricing and conditions, which then apply across all insurers. These negotiations influence how and when patients ultimately gain access to treatment.

Negotiations on Pricing and Reimbursement Conditions

Healthcare providers, particularly specialised clinics offering psychedelic treatments, negotiate service delivery and reimbursement terms with insurers. While ZiN sets the framework, insurers retain flexibility in tailoring contracts with these providers. These negotiations often centre on bundled payments, which cover the entire course of care—including diagnostics, drug administration, and therapy—over a defined period (e.g., 120 days or one year). This framework is primarily relevant for clinics and healthcare providers, as pharmaceutical manufacturers negotiate separate national-level pricing.

Insurers may separate costs into drug and non-drug elements for therapies combining pharmacological and psychotherapeutic components. This separation can lead to variability in how therapy components, such as integration sessions, are reimbursed. The variation in coverage rates—from nearly 100% with some contracts to as low as 45% without a contract—impacts patient access and influences the eligible population that clinics can effectively serve.[23]1 Understanding these coverage variations is crucial for healthcare providers planning to establish specialised treatment centres.

For clinics and care providers offering psychedelic therapies, insurer negotiations often focus on demonstrating value through measurable outcomes and efficient care delivery. These providers must structure their service offerings and demonstrate benefits within existing healthcare codes and reimbursement mechanisms. Care service delivery follows rules different from drug components, which operate under separate national pricing and reimbursement pathways.

Role of Insurers and Pilots

Four major insurers—Achmea (operating under brands like Zilveren Kruis, FBTO, and De Friesland), VGZ, CZ, and Menzis—dominate the insurance market in the Netherlands. Collectively, these insurers cover the majority of the population. While competition exists, insurers often adopt similar approaches to reimbursement decisions, particularly for high-profile therapies.

Pilot programs are a key mechanism for introducing innovative therapies in the Netherlands. Providers and insurers frequently collaborate on small-scale pilots to test new treatments, evaluate outcomes, and refine implementation models. These pilots allow insurers to de-risk adoption by gathering real-world evidence before committing to broader coverage. For psychedelic therapies, pilots could demonstrate efficacy and scalability, providing insurers with the data needed to support broader reimbursement.

Value-based arrangements are emerging in Dutch healthcare, historically driven by collaborations between hospitals and provider networks rather than directly with insurers. These provider-led models have achieved measurable improvements in patient outcomes by sharing data and best practices. While performance-linked payments do exist in theory—for example, to reduce hospital admissions in chronic conditions like COPD—the administrative burden of implementing full outcome-based contracts often limits their use.

These arrangements might influence the adoption of psychedelic therapies by healthcare institutions, though likely through simplified financial structures rather than complex outcome-based mechanisms. The focus typically remains on demonstrating value through established care pathways and reimbursement mechanisms, with healthcare institutions as the key partners in implementation.

Political and Advocacy Influence

While ZiN's decisions are grounded in clinical evidence and cost-effectiveness, political lobbying and advocacy efforts can significantly influence outcomes, particularly when highlighting disease severity and societal burden. High-impact therapies often attract media attention and patient advocacy, pushing policymakers to accelerate access.

For psychedelic therapies, patient advocacy groups (PAGs) can be crucial in demonstrating the significant burden of mental health conditions, their societal costs, and the critical need for innovation in treatment options. These partnerships are especially impactful in the mental health space, where both the severity of conditions and the historical lack of innovation can be powerful drivers for securing reimbursement and reducing stigma.

Political considerations may also affect budget allocations for mental health services, particularly as policymakers respond to growing awareness of unmet needs in areas like treatment-resistant depression (TRD) and PTSD. Developers should remain proactive in engaging with policymakers, framing psychedelic therapies as solutions to pressing public health challenges rather than niche treatments.

Infrastructure Readiness and Provider Networks

Reimbursement decisions must also account for infrastructure and provider readiness. Although the Netherlands’ clinical infrastructure is known as one of the best in the world, psychedelic therapies require dedicated treatment rooms, trained therapists, and monitoring protocols, raising questions about how quickly existing mental health services can adapt. Providers negotiate directly with insurers to establish service packages, and prices may vary based on regional capacity and expertise.

For example, some providers already operate under bundled payment models, offering comprehensive care packages for depression and anxiety disorders. Providers can adapt these frameworks for psychedelic therapies by integrating drug administration with therapy sessions into a single reimbursable unit. However, insurers may initially limit coverage to centres of excellence or pilot programs, requiring providers to scale up gradually as demand grows.

With infrastructure development, political advocacy, and pilot programs playing pivotal roles, the Netherlands represents a fertile but complex market for psychedelic therapies. Successful adoption will depend on proactive engagement with insurers, robust evidence generation, and scalable delivery models that align with existing healthcare frameworks.

Czech Republic

The reimbursement process in the Czech Republic builds upon the HTA evaluation conducted by the State Institute for Drug Control (SÚKL). After a favourable decision by SÚKL, the focus shifts to pricing agreements, insurance coverage, and implementation within the healthcare system. While the Czech system receives public funding through SHI, private insurers supplement coverage, especially for innovative therapies. The pathway for psychedelic therapies draws from prior experiences with novel treatments, such as esketamine and medicinal cannabis, indicating both openness to innovation and the need for structured reimbursement frameworks.

Implementation After SÚKL Approval

SÚKL's approval requires therapies to enter the Czech reimbursement system under the Act on Public Health Insurance. First, officials set the highest allowed price and establish payment methods. They base prices primarily on EU cost comparisons, specifically selecting the three lowest prices from a designated basket.

Specific indications and protocols determine reimbursement eligibility. For example, the 2022 agreement on esketamine (Spravato) stipulated that reimbursement applies only when administered in exceptional cases in specialised centres for TRD. At the end of 2024, Spravato gained standard reimbursement. Similar conditions are likely to govern psychedelics, particularly their combination with psychotherapy, which demands infrastructure and trained staff.

Insurance coverage typically follows the SÚKL decision, but insurers can impose additional conditions, particularly for therapies with high upfront costs or uncertain long-term outcomes. Budget impact analyses play a critical role, with insurers demanding evidence of economic sustainability. If the projected costs exceed predefined thresholds, risk-sharing agreements—such as price-volume arrangements or rebates—may be required to limit financial exposure.

Role of Health Insurance Providers

The Czech Republic’s healthcare system operates through SHI, with the General Health Insurance Company (VZP) covering most of the population and several smaller insurers providing additional options. Public insurers must follow SÚKL recommendations, but they retain some discretion in defining reimbursement conditions. For instance, the agreement on esketamine required joint approval from the Czech Psychiatric Society and insurers.

While SHI covers most psychiatric and psychotherapy services, innovative treatments such as ketamine therapy have often required partial reimbursement models. Patients may face co-payments, particularly for ancillary services, such as therapy sessions accompanying pharmacological interventions. Some clinics address affordability gaps by offering grant programs or leveraging partnerships with multiple insurers to create flexible financing options.

Although less dominant, private insurers can provide quicker access to therapies through performance-based reimbursement models. These agreements tie payments to treatment outcomes, enabling insurers to manage uncertainty while incentivising high-quality care. Psychedelic therapies may benefit from such models, especially if early pilot programs demonstrate measurable improvements in patient outcomes.

Regional Variability and Infrastructure Challenges

Although the Czech Republic has a centralised reimbursement framework, implementation can vary regionally, particularly for therapies requiring specialised infrastructure. Psychedelic therapies are likely to be limited initially to centres of excellence or university hospitals equipped with trained staff and monitoring facilities. Clinics offering ketamine psychotherapy already provide a precedent, operating within regulatory guidelines while negotiating tailored agreements with insurers.

Expanding access will depend on creating reimbursable codes for psychedelic therapy, which currently lacks standardised billing mechanisms. To enable broader adoption, stakeholders, including providers and advocacy groups, may need to push for legislative or administrative updates. Early engagement with insurers and policymakers is critical to streamlining this process and addressing gaps in existing frameworks.

Lessons from Ketamine and Cannabis Adoption

The Czech Republic’s experience with medicinal cannabis and esketamine provides insights into how psychedelic therapies might navigate the reimbursement landscape. Medicinal cannabis, legalised in 2013, required extensive coordination between regulators, prescribers, and insurers to establish prescribing protocols and pricing structures. Similarly, ketamine therapy—while partially reimbursed—has highlighted the importance of aligning pharmacological and therapeutic components under unified payment models.

These precedents suggest that psychedelic therapies could face stepwise adoption, starting with pilot programs in specialised centres before scaling more broadly. Such pilots demonstrate feasibility and generate real-world evidence to support reimbursement negotiations. They also allow insurers to test value-based agreements, tying payments to metrics like patient remission rates or reductions in hospital admissions.